Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026
Company Deals

AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development

Fineline Cube Oct 25, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...

Company Drug

EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC

Fineline Cube Oct 25, 2023

The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...

Company Drug

Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023

Fineline Cube Oct 25, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...

Company Deals Drug

AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment

Fineline Cube Oct 25, 2023

AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...

Company Drug

BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation...

Company

Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff

Fineline Cube Oct 25, 2023

Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...

Company Drug

Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors

Fineline Cube Oct 25, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...

Company Drug

Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment

Fineline Cube Oct 25, 2023

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...

Hospital Policy / Regulatory

Peking University Unveils National Standardized Pain Treatment Center in China

Fineline Cube Oct 25, 2023

Peking University People’s Hospital has officially unveiled the plaque for the National Standardized Pain Treatment...

Company Deals

Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D

Fineline Cube Oct 25, 2023

Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured...

Company Drug

China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery

Fineline Cube Oct 25, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...

Company Deals

Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development

Fineline Cube Oct 25, 2023

The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...

Company Deals

OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare

Fineline Cube Oct 25, 2023

US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...

Company Deals

BMS Regains Full Rights to Mavacamten in China and Asia from LianBio

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...

Company Drug

Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment

Fineline Cube Oct 25, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...

Company Drug

Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China

Fineline Cube Oct 25, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO

Fineline Cube Oct 24, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...

Company Drug

Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO

Fineline Cube Oct 24, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...

Company Drug

Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine

Fineline Cube Oct 24, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...

Policy / Regulatory

NMPA Implements New Measures for Drug Manufacturing Outsourcing by MAHs

Fineline Cube Oct 24, 2023

The National Medical Products Administration (NMPA) has issued a notice detailing new supervision and management...

Posts pagination

1 … 446 447 448 … 657

Recent updates

  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
  • Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China
  • Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.